Quote:

---

I'd feel more comfortable if the mild/moderate trial comprised 100-150 patients and the interim analysis for the severe trial 100, but given that the pandemic is starting to slow down and the difficulties for CYDY to quickly enroll, the smaller sizes might have been a blessing, provided leronlimab works as excellent as we all suspect.

---